NZ608070A - 2’-fluoro substituted carba-nucleoside analogs for antiviral treatment - Google Patents
2’-fluoro substituted carba-nucleoside analogs for antiviral treatmentInfo
- Publication number
- NZ608070A NZ608070A NZ608070A NZ60807011A NZ608070A NZ 608070 A NZ608070 A NZ 608070A NZ 608070 A NZ608070 A NZ 608070A NZ 60807011 A NZ60807011 A NZ 60807011A NZ 608070 A NZ608070 A NZ 608070A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- nucleoside analogs
- fluoro substituted
- antiviral treatment
- substituted
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 2
- -1 nucleoside phosphates Chemical class 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000021317 phosphate Nutrition 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- 125000004306 triazinyl group Chemical group 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/885,917 US7973013B2 (en) | 2009-09-21 | 2010-09-20 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
US13/050,820 US8455451B2 (en) | 2009-09-21 | 2011-03-17 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
PCT/US2011/029441 WO2012039791A1 (en) | 2010-09-20 | 2011-03-22 | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ608070A true NZ608070A (en) | 2015-11-27 |
Family
ID=47748238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ608070A NZ608070A (en) | 2010-09-20 | 2011-03-22 | 2’-fluoro substituted carba-nucleoside analogs for antiviral treatment |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP2619206A1 (en) |
JP (4) | JP2013538230A (en) |
KR (1) | KR101879887B1 (en) |
CN (1) | CN103108876A (en) |
AP (1) | AP3699A (en) |
AU (1) | AU2011306066B2 (en) |
BR (1) | BR112013008017A2 (en) |
CA (1) | CA2807496C (en) |
CL (1) | CL2013000727A1 (en) |
CO (1) | CO6680669A2 (en) |
CR (1) | CR20130172A (en) |
EA (1) | EA026523B1 (en) |
EC (1) | ECSP13012560A (en) |
IL (1) | IL225221A0 (en) |
MA (1) | MA34593B1 (en) |
MX (1) | MX2013003179A (en) |
NZ (1) | NZ608070A (en) |
PE (3) | PE20131165A1 (en) |
SG (1) | SG188223A1 (en) |
WO (1) | WO2012039791A1 (en) |
ZA (1) | ZA201301042B (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0911410A2 (en) | 2008-04-23 | 2015-10-06 | Gilead Sciences Inc | carba-nucleoside analogues for antiviral treatment |
SI2480559T1 (en) | 2009-09-21 | 2013-10-30 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-cyano-carbanucleoside analogs |
KR20200052384A (en) | 2010-07-19 | 2020-05-14 | 길리애드 사이언시즈, 인코포레이티드 | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
PT2595980E (en) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
CA2822037A1 (en) | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Methods for treating hcv |
TW201329096A (en) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
MD4589C1 (en) | 2011-09-16 | 2019-03-31 | Gilead Pharmasset Llc | Pharmaceutical composition comprising sofosbuvir and uses thereof for treating hepatitis C virus |
NZ625087A (en) | 2013-01-31 | 2017-05-26 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
UA119050C2 (en) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections |
TWI678369B (en) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines useful for treating respiratory syncitial virus infections |
CN104230985B (en) * | 2014-09-01 | 2017-01-18 | 北京天弘天达医药科技有限公司 | Preparation method of (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate |
TWI698444B (en) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | Methods for the preparation of ribosides |
DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
CA2998189C (en) | 2015-09-16 | 2021-08-03 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
CN110869028B (en) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | Method of treating feline coronavirus infection |
CN115403626A (en) | 2017-05-01 | 2022-11-29 | 吉利德科学公司 | Novel crystalline forms |
US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
SG11202004403QA (en) | 2017-12-07 | 2020-06-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2021154687A1 (en) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
CN115298181A (en) | 2020-03-12 | 2022-11-04 | 吉利德科学公司 | Process for preparing 1' -cyanonucleosides |
EP4132651A1 (en) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
CA3179226A1 (en) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Remdesivir treatment methods |
CN115996928A (en) | 2020-06-24 | 2023-04-21 | 吉利德科学公司 | 1' -cyanonucleoside analogs and uses thereof |
PE20231983A1 (en) | 2020-08-27 | 2023-12-12 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
WO2023167944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
WO2023207942A1 (en) * | 2022-04-25 | 2023-11-02 | 北京沐华生物科技有限责任公司 | Nucleoside drug for treating or preventing coronavirus infection, and use thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
CA2083386C (en) | 1990-06-13 | 1999-02-16 | Arnold Glazier | Phosphorous prodrugs |
EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
DE19912636A1 (en) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclic heterocycles, processes for their preparation and their use as herbicides and pharmaceutical agents |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
EA200200778A1 (en) | 2000-02-18 | 2003-06-26 | Шайре Байокем Инк. | METHOD OF TREATMENT OR PREVENTION OF HEPATITIS C INFECTION IN THE ORGANISM ORGANISM, PHARMACEUTICAL COMPOSITION AGAINST FLAVIVIRUS, CONNECTION OF FORMULA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION OF EFFECTECH EFFECTURES Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION INEKEKHEKUSA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PROTECTION |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
KR101201552B1 (en) | 2000-10-18 | 2012-11-15 | 파마셋 인코포레이티드 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
RS50236B (en) * | 2001-01-22 | 2009-07-15 | Merck & Co.Inc., | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
CN1849142A (en) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2'-branched nucleosides and flaviviridae mutation |
EP2345661A1 (en) * | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
AU2005285045B2 (en) | 2004-09-14 | 2011-10-13 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
CA2584367A1 (en) * | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
CN101043893A (en) * | 2004-10-21 | 2007-09-26 | 默克公司 | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
JP2010515680A (en) | 2007-01-05 | 2010-05-13 | メルク・シャープ・エンド・ドーム・コーポレイション | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infections |
US8440813B2 (en) | 2007-01-12 | 2013-05-14 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
EP2125819B1 (en) | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
WO2008141079A1 (en) | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer |
BRPI0911410A2 (en) | 2008-04-23 | 2015-10-06 | Gilead Sciences Inc | carba-nucleoside analogues for antiviral treatment |
WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
EP2313102A2 (en) * | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
PE20160858A1 (en) * | 2009-02-10 | 2016-09-03 | Gilead Sciences Inc | CARBA-NUCLEOSIDIC ANALOGS FOR ANTIVIRAL TREATMENT |
PE20210668A1 (en) * | 2009-09-21 | 2021-04-05 | Gilead Sciences Inc | CARBA-NUCLEOSID ANALOGS REPLACED WITH 2'-FLUORINE ANTIVIRALS |
-
2011
- 2011-03-22 BR BR112013008017A patent/BR112013008017A2/en not_active Application Discontinuation
- 2011-03-22 CN CN2011800449231A patent/CN103108876A/en active Pending
- 2011-03-22 PE PE2013000530A patent/PE20131165A1/en active IP Right Grant
- 2011-03-22 PE PE2022003082A patent/PE20230684A1/en unknown
- 2011-03-22 EP EP11715792.5A patent/EP2619206A1/en not_active Withdrawn
- 2011-03-22 AP AP2013006767A patent/AP3699A/en active
- 2011-03-22 JP JP2013529139A patent/JP2013538230A/en not_active Withdrawn
- 2011-03-22 SG SG2013011325A patent/SG188223A1/en unknown
- 2011-03-22 WO PCT/US2011/029441 patent/WO2012039791A1/en active Application Filing
- 2011-03-22 PE PE2017001530A patent/PE20171624A1/en unknown
- 2011-03-22 MX MX2013003179A patent/MX2013003179A/en not_active Application Discontinuation
- 2011-03-22 KR KR1020137010012A patent/KR101879887B1/en active IP Right Grant
- 2011-03-22 AU AU2011306066A patent/AU2011306066B2/en active Active
- 2011-03-22 NZ NZ608070A patent/NZ608070A/en unknown
- 2011-03-22 CA CA2807496A patent/CA2807496C/en active Active
- 2011-03-22 EA EA201390141A patent/EA026523B1/en unknown
-
2013
- 2013-02-07 ZA ZA2013/01042A patent/ZA201301042B/en unknown
- 2013-02-26 CO CO13038918A patent/CO6680669A2/en not_active Application Discontinuation
- 2013-03-14 IL IL225221A patent/IL225221A0/en unknown
- 2013-03-18 CL CL2013000727A patent/CL2013000727A1/en unknown
- 2013-04-04 MA MA35795A patent/MA34593B1/en unknown
- 2013-04-17 CR CR20130172A patent/CR20130172A/en unknown
- 2013-04-18 EC ECSP13012560 patent/ECSP13012560A/en unknown
-
2016
- 2016-01-18 JP JP2016006833A patent/JP2016074732A/en not_active Withdrawn
-
2017
- 2017-04-10 JP JP2017077366A patent/JP6475280B2/en active Active
-
2018
- 2018-09-18 JP JP2018173758A patent/JP2019014726A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP6475280B2 (en) | 2019-02-27 |
MA34593B1 (en) | 2013-10-02 |
CL2013000727A1 (en) | 2013-08-23 |
AP2013006767A0 (en) | 2013-03-31 |
PE20131165A1 (en) | 2013-10-14 |
KR20130110168A (en) | 2013-10-08 |
IL225221A0 (en) | 2013-06-27 |
EP2619206A1 (en) | 2013-07-31 |
JP2017119726A (en) | 2017-07-06 |
CO6680669A2 (en) | 2013-05-31 |
EA026523B1 (en) | 2017-04-28 |
BR112013008017A2 (en) | 2016-06-14 |
PE20171624A1 (en) | 2017-11-02 |
SG188223A1 (en) | 2013-04-30 |
JP2019014726A (en) | 2019-01-31 |
CA2807496C (en) | 2019-01-22 |
AU2011306066A1 (en) | 2013-02-28 |
MX2013003179A (en) | 2013-04-24 |
ZA201301042B (en) | 2014-07-30 |
CR20130172A (en) | 2013-05-29 |
ECSP13012560A (en) | 2013-06-28 |
EA201390141A1 (en) | 2013-09-30 |
AU2011306066B2 (en) | 2015-01-29 |
PE20230684A1 (en) | 2023-04-21 |
JP2013538230A (en) | 2013-10-10 |
KR101879887B1 (en) | 2018-07-18 |
AP3699A (en) | 2016-05-31 |
WO2012039791A1 (en) | 2012-03-29 |
CA2807496A1 (en) | 2012-03-29 |
JP2016074732A (en) | 2016-05-12 |
CN103108876A (en) | 2013-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ608070A (en) | 2’-fluoro substituted carba-nucleoside analogs for antiviral treatment | |
NZ599402A (en) | 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
EA201691623A1 (en) | 2'-Fluoro-substituted Carbanulosis Analogs for antiviral treatment | |
MX2013011915A (en) | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment. | |
MX2013000656A (en) | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs. | |
NZ593647A (en) | Synthesis of purine nucleosides | |
EA201590943A1 (en) | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES | |
CO6321235A2 (en) | CARBA-NUCLEOSID ANALOGS 1 SUBSTITUTED FOR ANTIVIRAL TREATMENT | |
EA201491179A1 (en) | 2 ', 4'-DIFFOROR-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS AN INHIBITORS REPLICATION RNA HEPATITIS C VIRUS | |
MX2010013768A (en) | Nucleoside cyclicphosphates. | |
TN2012000358A1 (en) | Hepatitis c virus inhibitors | |
MD20150036A2 (en) | 2'-Chloro nucleoside analogs for HCV infection | |
MX362060B (en) | Antiviral compounds inhibitors of hcv ns5b. | |
NZ629428A (en) | Substituted nucleosides, nucleotides and analogs thereof | |
NZ631182A (en) | Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds | |
GB0623493D0 (en) | Chemical compounds | |
EA201491180A1 (en) | 4'-AZIDO, 3'-FLUORINE-SUBSTITUTED DERIVATIVES OF NUCLEOSIDES AS AN INHIBITORS OF REPLICATION OF RNA HEPATITIS C VIRUS | |
MX2012008443A (en) | 4 ' - azido - nucleosides as anti - hcv compunds. | |
PE20170203A1 (en) | NUCLEOSIDE DERIVATIVES SUBSTITUTED WITH 4'-DIFLUOROMETHYL AS INHIBITORS OF INFLUEZA RNA REPLICATION | |
MX2011012541A (en) | Heterocyclic antiviral compound. | |
MX2011011112A (en) | Heterocyclic antiviral compounds. | |
MX2015008661A (en) | Process for the preparation of a fluorolacton derivative. | |
MX2012002958A (en) | Heterocyclic antiviral compounds. | |
UA102687C2 (en) | 1'-substituted carba-nucleoside analogs for antiviral treatment | |
NZ725365A (en) | Antiviral compounds inhibitors of hcv ns5b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 MAR 2018 BY COMPUTER PACKAGES INC Effective date: 20160318 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2019 BY COMPUTER PACKAGES INC Effective date: 20180302 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2020 BY COMPUTER PACKAGES INC Effective date: 20190302 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2021 BY COMPUTER PACKAGES INC Effective date: 20200303 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2022 BY CPA GLOBAL Effective date: 20210204 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2023 BY CPA GLOBAL Effective date: 20220204 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2024 BY CPA GLOBAL Effective date: 20230203 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240208 |